U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417501) titled 'Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification' on Feb. 10.
Brief Summary: The goal of this clinical trial is to learn if the combination of lenvatinib and a PD-1 inhibitor (a type of immunotherapy) works to treat advanced solid tumors that have a specific genetic change called "11q13 amplification". It will also learn about the safety of this combination. The main questions it aims to answer are:
How many participants' tumors shrink or stop growing after receiving the combination therapy? What side effects do participants have when taking this combination therapy? All participants in this study w...